UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CONSULTING, ADVISORY & MEDCOMMS

L.E.K. Consulting

Global strategy consulting across healthcare and life sciences

L.E.K. Consulting logo

L.E.K. Consulting

Consulting, Advisory & MedCommsLondon, United Kingdom

Global strategy consulting across healthcare and life sciences

Visit Website

About L.E.K. Consulting

Founded in London in 1983, L.E.K. Consulting has built a reputation as one of the most analytically rigorous strategy consultancies serving the life sciences and healthcare sectors. Operating across more than 20 offices worldwide, the firm advises pharmaceutical companies, biotechnology firms, medical device manufacturers, private equity investors, and healthcare providers on their most consequential strategic decisions.

Within the pharma and life sciences space, L.E.K. is particularly well known for its work on commercial strategy and market access, helping clients assess the commercial viability of pipeline assets, define pricing and reimbursement pathways, and build launch strategies for new therapies. Its teams combine deep sector expertise with a quantitative, evidence-driven approach that has made the firm a trusted adviser on transactions, portfolio decisions, and growth strategy across the industry.

The firm also has a well-established practice advising private equity and corporate clients on life sciences transactions, including due diligence, post-merger integration, and buy-and-build strategies. This transactional capability, combined with its operational and commercial advisory work, positions L.E.K. across the full investment and growth cycle for healthcare businesses.

L.E.K. operates as a private partnership and serves clients globally, with particular strength in North America, Europe, and Asia-Pacific. Its healthcare and life sciences practice spans oncology, rare diseases, specialty pharma, diagnostics, and medical technology, reflecting the breadth of the sector it covers.

Further information is available at lek.com.

Areas of Expertise

Commercial StrategyMarket AccessOncologyRare DiseaseSpecialty Pharma

Services & Capabilities

Commercial StrategyMarket AccessOncologyRare DiseaseSpecialty Pharma
Similar Companies

More in Consulting, Advisory & MedComms

A

Aagami

With a senior partner network accumulating more than 250 years of combined experience and a C-level relationship portfolio cultivated over two decades, Aagami, Inc. operates as a high-access consultancy for life sciences organisations seeking to expand across borders. Headquartered in Naperville, Illinois, the firm has completed more than 200 assignments for over 110 clients spanning pharmaceuticals, biotechnology, medical devices and technology, consumer healthcare, CROs, CDMOs, and academia. The core value proposition is bandwidth extension: Aagami supplements a client's in-house capability where geography, language, or resource constraints limit reach. Its four principal service lines are strategic consulting, technology licensing, business research and market intelligence, and business development support. A key differentiator is the firm's deep understanding of business and socio-cultural differences across global markets, enabling clients to navigate regulatory environments, commercial customs, and stakeholder expectations that vary significantly by region. Clients engaging Aagami typically seek access to decision-makers that are difficult to approach through internal channels. The firm's approach centres on leveraging long-standing executive relationships and cross-sector experience to reduce the time, effort, and cost involved in international business development and technology licensing transactions. Its newsletter and publications programme, including the long-running Pullan's Pieces series, reflects the firm's commitment to sharing market intelligence with the broader life sciences community. Further information is available at aagami.com.

View profile
A

AET

Part of the 100% family-owned Tiefenbacher Group, AET provides end-to-end pharmaceutical development and out-licensing solutions spanning more than 80 countries. With over 900 employees and its own laboratories and manufacturing facilities, the group builds efficient supply chains for marketing partners across every major regulated market, removing the full burden of development risk from commercial partners and accelerating their time-to-market. Out-Licensing Model and Core Capabilities AET's business model centres on developing, manufacturing, and registering pharmaceutical products before licensing them to partners worldwide. The portfolio covers value-added generic drug development, innovative medicines, and high-potent compounds, addressing three strategic pillars: better affordability, broader global availability, and genuine therapeutic improvement. From early formulation through regulatory dossier preparation, clinical supply, and multi-market registration, AET manages the entire product life cycle on behalf of its licensing partners. A recognised strength is the organisation's expertise in preparing best-in-class regulatory dossiers that support complex simultaneous launches across multiple jurisdictions. This capability has attracted some of the world's most trusted pharmaceutical brands as long-term partners, underpinned by consistent manufacturing quality and a scalable supply-chain infrastructure that handles both small-molecule and high-potency product categories. The Tiefenbacher Group's integrated model, combining in-house R&D, production, and regulatory affairs under one ownership structure, offers partners a single point of accountability from concept to commercial launch. AET's reach across diverse regulatory environments, from the European Medicines Agency to emerging-market agencies, makes it a capable partner for companies seeking to extend the commercial footprint of established or novel pharmaceutical products. Further information is available at aet.eu.

View profile
A

Adelphi Communications

Adelphi Communications brings together real-world evidence, HEOR data, clinical evidence, and patient-reported outcomes into a unified, insight-led approach designed to optimise patient outcomes across the healthcare industry. The agency operates as a global medical communications partner, with offices in the UK and USA, and forms part of the wider Adelphi Group network of specialist healthcare consultancies. Capabilities and Approach At the core of Adelphi Communications' model is a highly collaborative way of working, grounded in knowledge and integrity. The agency's team draws from backgrounds in scientific and medical research, enabling it to develop creative, evidence-informed solutions to the complex challenges facing pharmaceutical and healthcare clients. Its work spans five principal disciplines, including scientific publications, congress support, digital medical education, and strategic medical communications planning. The agency's distinctive methodology lies in how it synthesises multiple data sources. By combining real-world evidence and HEOR data with clinical evidence and patient-reported outcomes, Adelphi Communications equips clients with a cohesive roadmap rather than fragmented analysis from isolated data streams. This evidence synthesis approach is particularly suited to healthcare companies navigating complex regulatory, market access, and clinical evidence environments. Adelphi Communications recruits across its UK and USA offices, offering professionals an environment with intensive on-the-job coaching and a structured programme of targeted training, making it a recognised employer within the medical communications sector. Further information is available at adelphicommunications.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy